Posted in Market Access UCB brings first therapy for rare disease TK2d to EU March 31, 2026 Pharmaphorum The EU has approved UCB’s Kygevvi for rare disease TK2d, and Sanofi’s acute GvHD therapy Rezurock, in a pair of decisions announced this morning. Market AccessRare DiseaseRead full story